1289646-76-9

Basic information

• Product Name: (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid
• Synonyms: (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid
• CAS NO: 1289646-76-9
• Molecular Formula: C₁₅H₂₁NO₆S
• Molecular Weight: 343.39534
• EINECS: -0
• Mol File: 1289646-76-9.mol

Chemical Properties

• Boiling Point: 572.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.269±0.06 g/cm3(Predicted)
• PKA: 3.74±0.10(Predicted)
• CAS DataBase Reference: (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid(1289646-76-9)
• EPA Substance Registry System: (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid(1289646-76-9)

Safety Data

• Hazardous Substances Data: 1289646-76-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Biotechnology Industries:
(S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid is used as a building block for the synthesis of other compounds due to its unique structural features. It is particularly valuable in the development of new pharmaceuticals and biotechnological products, where its versatility allows for the creation of a wide range of biologically active molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid is used as an intermediate for the synthesis of potential drug candidates. Its protected amino group and functionalized phenyl ring provide a foundation for the development of molecules with specific biological activities, contributing to the discovery of new therapeutic agents.
Used in Drug Discovery:
(S)-2-(tert-butoxycarbonylamino)-3-(3-(methylsulfonyl)phenyl) propanoic acid plays a crucial role in drug discovery, where its structural attributes enable the design and synthesis of novel compounds with potential therapeutic effects. Its use in this context aids researchers in identifying and optimizing new drug candidates for various medical conditions.

Upstream product

• 82278-73-7 (2S)-3-(3-bromophenyl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 67-71-0 dimethylsulfone 
• 82311-69-1 (S)-2-amino-3-(3-bromophenyl)propanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 20277-69-4 sodium methansulfinate 

Downstream Products

• 1194550-59-8 (2S)-2-amino-3-(3-(methanesulfonyl)phenyl)propionic acid benzyl ester hydrochloride 
• 1194550-63-4 C₄₆H₄₀Cl₂N₂O₅S 
• 1194550-65-6 benzyl (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-[3-(methylsulfonyl)phenyl]propanoate hydrochloride 
• 1194550-67-8 ((S)-benzyl 2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-methylsulfonyl)phenyl)propanoate 
• 1025967-78-5 (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 
• 1289646-78-1 (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate 

Relevant articles and documents

Preparation method of lifitegrast intermediate

The invention relates to a preparation method of a lifitegrast intermediate. The preparation method is implemented by the following route, has the advantages of short synthesis route, high yield and high safety, and is simple and convenient to operate and suitable for industrial production. According to the preparation method, a compound II reacts with metal zinc in an organic solvent to generatean organic zinc reagent, a compound I carries out a coupling reaction with the organic zinc reagent, a palladium reagent and a phosphorus ligand to obtain a compound III, and Boc protecting groups ofthe compound III are removed to obtain a compound IV, wherein R1 and R2 groups are respectively and independently selected from methyl, ethyl, vinyl, n-propyl, isopropyl, propenyl, propynyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, butenyl, cyclobutyl, n-pentyl, iso-pentyl, cyclopentyl, n-hexyl, cyclohexyl, phenyl and benzyl.

LFA-1 INHIBITOR AND POLYMORPH THEREOF

Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA -1 mediated diseases are also disclosed.

Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye

LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of T-cell receptor signaling. The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was observed in animal models and patients diagnosed with dry eye. Therefore, it has been hypothesized that small molecule LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye. In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic solution for treating dry eye.